首页 > 最新文献

Surgical Oncology-Oxford最新文献

英文 中文
Organ-specific variations in tumor marker dynamics in postoperative pancreatic cancer recurrence: Trends in lung and liver recurrence highlighting biological heterogeneity 胰腺癌术后复发中肿瘤标志物动态的器官特异性变化:肺癌和肝癌复发趋势凸显生物异质性。
IF 2.3 4区 医学 Q3 ONCOLOGY Pub Date : 2024-07-04 DOI: 10.1016/j.suronc.2024.102103
Satoru Miyahara, Hidenori Takahashi, Yoshito Tomimaru, Shogo Kobayashi, Kazuki Sasaki, Yoshifumi Iwagami, Daisaku Yamada, Hirofumi Akita, Takehiro Noda, Yuichiro Doki, Hidetoshi Eguchi

Background/Objectives

Although tumor recurrence after surgical resection in pancreatic cancer (PC) is generally considered incurable, it is well-accepted that clinical presentations and outcomes vary according to the recurrent sites (e.g., liver vs. lung recurrence), suggesting a possible biological inhomogeneity of PC recurrence. Understanding the behavior of biological factors, specifically tumor markers (TMs), at different recurrence sites may contribute to individualized treatment strategies. Therefore, this study aimed to compare the dynamics of pre-recurrence TMs at liver and lung recurrence sites.

Methods

Patients with isolated postoperative liver or lung recurrence as their first recurrence were enrolled. Starting from the recurrence date confirmed by imaging examinations, the values of TMs (carbohydrate antigen 19-9: CA19-9; carcinoembryonic antigen: CEA) were retrospectively evaluated 6 and 3 months before recurrence and at the time of recurrence.

Results

Patients with liver recurrence displayed a significant increase in CA19-9 and CEA levels from as early as 6 months before recurrence. Contrastingly, patients with lung recurrence demonstrated a significant elevation of CA19-9 levels starting from 3 months before recurrence, with no increase in CEA levels, even at the time of recurrence. The relative change in CA19-9 and CEA levels during each period were significantly lower in patients with lung recurrence.

Conclusions

Both TMs exhibited organ-specific variations in patients with postoperative PC recurrence. This disparity may reflect the biological heterogeneity of PC between recurrence patterns, thereby highlighting the importance of conducting postoperative follow-up with consideration of this fact.

背景/目的:尽管胰腺癌(PC)手术切除后肿瘤复发通常被认为是不可治愈的,但公认的是,不同复发部位(如肝复发与肺复发)的临床表现和预后各不相同,这表明 PC 复发可能存在生物学不均一性。了解不同复发部位的生物因素,特别是肿瘤标志物(TMs)的行为可能有助于制定个体化治疗策略。因此,本研究旨在比较肝脏和肺部复发部位复发前TMs的动态变化:方法:将术后肝脏或肺部孤立复发作为首次复发的患者纳入研究。从影像学检查确认的复发日期开始,回顾性评估复发前 6 个月和 3 个月以及复发时的 TMs(碳水化合物抗原 19-9:CA19-9;癌胚抗原:CEA)值:结果:肝癌复发患者的 CA19-9 和 CEA 水平早在复发前 6 个月就显著升高。相反,肺部复发患者的 CA19-9 水平从复发前 3 个月开始显著升高,而 CEA 水平即使在复发时也没有升高。肺部复发患者在每个时期的CA19-9和CEA水平相对变化明显较低:结论:PC 术后复发患者的两种 TM 均表现出器官特异性变化。结论:PC 术后复发患者的两种 TM 均表现出器官特异性差异,这种差异可能反映了不同复发模式下 PC 的生物学异质性,因此强调了术后随访的重要性。
{"title":"Organ-specific variations in tumor marker dynamics in postoperative pancreatic cancer recurrence: Trends in lung and liver recurrence highlighting biological heterogeneity","authors":"Satoru Miyahara,&nbsp;Hidenori Takahashi,&nbsp;Yoshito Tomimaru,&nbsp;Shogo Kobayashi,&nbsp;Kazuki Sasaki,&nbsp;Yoshifumi Iwagami,&nbsp;Daisaku Yamada,&nbsp;Hirofumi Akita,&nbsp;Takehiro Noda,&nbsp;Yuichiro Doki,&nbsp;Hidetoshi Eguchi","doi":"10.1016/j.suronc.2024.102103","DOIUrl":"10.1016/j.suronc.2024.102103","url":null,"abstract":"<div><h3>Background/Objectives</h3><p>Although tumor recurrence after surgical resection in pancreatic cancer (PC) is generally considered incurable, it is well-accepted that clinical presentations and outcomes vary according to the recurrent sites (e.g., liver vs. lung recurrence), suggesting a possible biological inhomogeneity of PC recurrence. Understanding the behavior of biological factors, specifically tumor markers (TMs), at different recurrence sites may contribute to individualized treatment strategies. Therefore, this study aimed to compare the dynamics of pre-recurrence TMs at liver and lung recurrence sites.</p></div><div><h3>Methods</h3><p>Patients with isolated postoperative liver or lung recurrence as their first recurrence were enrolled. Starting from the recurrence date confirmed by imaging examinations, the values of TMs (carbohydrate antigen 19-9: CA19-9; carcinoembryonic antigen: CEA) were retrospectively evaluated 6 and 3 months before recurrence and at the time of recurrence.</p></div><div><h3>Results</h3><p>Patients with liver recurrence displayed a significant increase in CA19-9 and CEA levels from as early as 6 months before recurrence. Contrastingly, patients with lung recurrence demonstrated a significant elevation of CA19-9 levels starting from 3 months before recurrence, with no increase in CEA levels, even at the time of recurrence. The relative change in CA19-9 and CEA levels during each period were significantly lower in patients with lung recurrence.</p></div><div><h3>Conclusions</h3><p>Both TMs exhibited organ-specific variations in patients with postoperative PC recurrence. This disparity may reflect the biological heterogeneity of PC between recurrence patterns, thereby highlighting the importance of conducting postoperative follow-up with consideration of this fact.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141581457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and efficacy of thermal ablation of adrenal metastases secondary to lung cancer 肺癌继发肾上腺转移热消融的安全性和有效性
IF 2.3 4区 医学 Q3 ONCOLOGY Pub Date : 2024-07-03 DOI: 10.1016/j.suronc.2024.102102
Andrew M. Mendez , Elena N. Petre , Etay Ziv , Fourat Ridouani , Stephen B. Solomon , Vlasios Sotirchos , Ken Zhao , Erica S. Alexander

Objectives

Assess safety and efficacy of thermal ablation for adrenal metastases (AM) secondary to non-small cell lung cancer (NSCLC).

Materials and methods

This retrospective study included patients with NSCLC AM treated with thermal ablation between 2/2010–11/2021. Local tumor progression free survival (LTPFS) and overall survival (OS) were calculated using Kaplan-Meier method. Adverse events were graded using Common Terminology Criteria for Adverse Events v5.

Results

Seven patients (mean age ± SD, 63.9 ± 12.5 years; 6 males) with seven AM were treated in eight sessions. Retreatment was performed in one patient with residual disease. Five sessions were with microwave ablation and 3 with radiofrequency ablation. Mean tumor size was 20.1 ± 7.0 mm. Median number of ablation probes used was 1 (range, 1–5), with a median of 3 activations (range, 1–3), and average ablation time of 14.4 ± 15.0 minutes. Response based on RECIST v 1.1 or PERCIST criteria revealed stable disease in 1 tumor, progression of disease in 3 tumors (one was re-ablated), and partial response in 3 tumors. Median LTPFS was not reached (NR) [95 % CI: 1- NR]. Median OS was 47.97 months (95 % CI: 18.63- NR).

Intraprocedural hypertension (blood pressure ≥180 mmHg) occurred during 5/8 (62.5 %) sessions and intraoperative tachycardia occurred during 2/8 (25 %) sessions. Complications within one month of ablation occurred in 3/8 (37.5 %) sessions: grade 2 pneumothorax, grade 1 hematuria, and grade 2 adrenal insufficiency.

Conclusions

In this small series, thermal ablation for NSCLC AM resulted in prolonged local control and OS with no major complications.

目的评估热消融治疗非小细胞肺癌(NSCLC)继发性肾上腺转移瘤(AM)的安全性和有效性。材料和方法这项回顾性研究纳入了2010年2月至2021年11月期间接受热消融治疗的NSCLC AM患者。采用 Kaplan-Meier 法计算无局部肿瘤进展生存期(LTPFS)和总生存期(OS)。结果7名患者(平均年龄± SD,63.9± 12.5岁;6名男性)共接受了8次治疗,其中有7例AM。对一名有残留疾病的患者进行了再治疗。其中五次采用微波消融术,三次采用射频消融术。肿瘤平均大小为 20.1 ± 7.0 毫米。所用消融探头的中位数为 1 个(1-5 个不等),激活次数中位数为 3 次(1-3 次不等),平均消融时间为 14.4 ± 15.0 分钟。根据 RECIST v 1.1 或 PERCIST 标准得出的反应结果显示,1 例肿瘤病情稳定,3 例肿瘤病情进展(其中 1 例再次消融),3 例肿瘤部分反应。中位 LTPFS 未达到 (NR) [95 % CI: 1- NR]。术中高血压(血压≥180 mmHg)发生在 5/8 次(62.5%)手术中,术中心动过速发生在 2/8 次(25%)手术中。3/8(37.5%)次消融术后一个月内出现并发症:2级气胸、1级血尿和2级肾上腺功能不全。
{"title":"Safety and efficacy of thermal ablation of adrenal metastases secondary to lung cancer","authors":"Andrew M. Mendez ,&nbsp;Elena N. Petre ,&nbsp;Etay Ziv ,&nbsp;Fourat Ridouani ,&nbsp;Stephen B. Solomon ,&nbsp;Vlasios Sotirchos ,&nbsp;Ken Zhao ,&nbsp;Erica S. Alexander","doi":"10.1016/j.suronc.2024.102102","DOIUrl":"https://doi.org/10.1016/j.suronc.2024.102102","url":null,"abstract":"<div><h3>Objectives</h3><p>Assess safety and efficacy of thermal ablation for adrenal metastases (AM) secondary to non-small cell lung cancer (NSCLC).</p></div><div><h3>Materials and methods</h3><p>This retrospective study included patients with NSCLC AM treated with thermal ablation between 2/2010–11/2021. Local tumor progression free survival (LTPFS) and overall survival (OS) were calculated using Kaplan-Meier method. Adverse events were graded using Common Terminology Criteria for Adverse Events v5.</p></div><div><h3>Results</h3><p>Seven patients (mean age ± SD, 63.9 ± 12.5 years; 6 males) with seven AM were treated in eight sessions. Retreatment was performed in one patient with residual disease. Five sessions were with microwave ablation and 3 with radiofrequency ablation. Mean tumor size was 20.1 ± 7.0 mm. Median number of ablation probes used was 1 (range, 1–5), with a median of 3 activations (range, 1–3), and average ablation time of 14.4 ± 15.0 minutes. Response based on RECIST v 1.1 or PERCIST criteria revealed stable disease in 1 tumor, progression of disease in 3 tumors (one was re-ablated), and partial response in 3 tumors. Median LTPFS was not reached (NR) [95 % CI: 1- NR]. Median OS was 47.97 months (95 % CI: 18.63- NR).</p><p>Intraprocedural hypertension (blood pressure ≥180 mmHg) occurred during 5/8 (62.5 %) sessions and intraoperative tachycardia occurred during 2/8 (25 %) sessions. Complications within one month of ablation occurred in 3/8 (37.5 %) sessions: grade 2 pneumothorax, grade 1 hematuria, and grade 2 adrenal insufficiency.</p></div><div><h3>Conclusions</h3><p>In this small series, thermal ablation for NSCLC AM resulted in prolonged local control and OS with no major complications.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141540007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of preoperative breast MRI on the therapeutic management of breast cancer patients 术前乳腺磁共振成像对乳腺癌患者治疗管理的影响。
IF 2.3 4区 医学 Q3 ONCOLOGY Pub Date : 2024-07-02 DOI: 10.1016/j.suronc.2024.102095
Zohar Goren , Tammy Zioni , Dina Lev , Yaron Cohen , Zvi Howard Perry

Background

The role of preoperative breast MRI to evaluate the extent of disease in breast cancer patients is considered controversial. We aimed at assessing the effect of breast MRI on the management of newly diagnosed breast cancer.

Materials

A retrospective review of 202 consecutively seen patients who were newly diagnosed with breast cancer and who underwent preoperative breast MRIs at Assuta Ashdod between June 1, 2017, and June 1, 2020. Data included discovering suspicious lesions by conventional imaging, MRI findings, and surgical pathology results. This was analyzed to determine whether the MRI changed the management and whether it had a justified or unjustified effect on the treatment.

Results

The mean age was 54.51 (standard deviation, 11.34 years). Breast MRI revealed additional findings in 56 % of patients and modified therapeutic management in 32 % of the cases evaluated, having a justified effect in 87.6 %. Patients with changed management had a statistically significantly higher mastectomy rate (36 %) than those who did not (14 %). No statistically significant association was found between independent variables such as breast density, tumor location on the breast, type of tumor, patient's demographic information, etc. And whether MRI findings changed the initial treatment plan.

Conclusions

MRI played an essential role in the preoperative staging of breast cancer in our study, modifying therapeutic planning in approximately one-third of the cases and having a justified effect on most of them. We, therefore, support preoperative breast MRI in newly diagnosed breast cancer patients.

背景:术前乳腺 MRI 在评估乳腺癌患者疾病范围方面的作用存在争议。我们旨在评估乳腺磁共振成像对新诊断乳腺癌治疗的影响:对 2017 年 6 月 1 日至 2020 年 6 月 1 日期间在阿苏塔阿什杜德接受术前乳腺 MRI 检查的 202 名新诊断为乳腺癌的连续就诊患者进行回顾性审查。数据包括通过常规成像发现的可疑病灶、核磁共振成像结果和手术病理结果。对这些数据进行分析,以确定核磁共振成像是否改变了治疗方案,以及对治疗产生了合理或不合理的影响:平均年龄为 54.51 岁(标准差为 11.34 岁)。56%的患者通过乳腺核磁共振检查发现了其他病变,32%的病例通过核磁共振检查改变了治疗方案,87.6%的病例通过核磁共振检查改变了治疗方案。据统计,改变治疗方法的患者的乳房切除率(36%)明显高于未改变治疗方法的患者(14%)。乳腺密度、肿瘤在乳房上的位置、肿瘤类型、患者人口统计学信息等自变量之间没有统计学意义上的关联。以及核磁共振成像结果是否改变了最初的治疗方案:在我们的研究中,核磁共振成像在乳腺癌术前分期中发挥了重要作用,约有三分之一的病例修改了治疗方案,并且对大多数病例产生了合理的影响。因此,我们支持对新诊断的乳腺癌患者进行术前乳腺磁共振成像检查。
{"title":"The impact of preoperative breast MRI on the therapeutic management of breast cancer patients","authors":"Zohar Goren ,&nbsp;Tammy Zioni ,&nbsp;Dina Lev ,&nbsp;Yaron Cohen ,&nbsp;Zvi Howard Perry","doi":"10.1016/j.suronc.2024.102095","DOIUrl":"10.1016/j.suronc.2024.102095","url":null,"abstract":"<div><h3>Background</h3><p>The role of preoperative breast MRI to evaluate the extent of disease in breast cancer patients is considered controversial. We aimed at assessing the effect of breast MRI on the management of newly diagnosed breast cancer.</p></div><div><h3>Materials</h3><p>A retrospective review of 202 consecutively seen patients who were newly diagnosed with breast cancer and who underwent preoperative breast MRIs at Assuta Ashdod between June 1, 2017, and June 1, 2020. Data included discovering suspicious lesions by conventional imaging, MRI findings, and surgical pathology results. This was analyzed to determine whether the MRI changed the management and whether it had a justified or unjustified effect on the treatment.</p></div><div><h3>Results</h3><p>The mean age was 54.51 (standard deviation, 11.34 years). Breast MRI revealed additional findings in 56 % of patients and modified therapeutic management in 32 % of the cases evaluated, having a justified effect in 87.6 %. Patients with changed management had a statistically significantly higher mastectomy rate (36 %) than those who did not (14 %). No statistically significant association was found between independent variables such as breast density, tumor location on the breast, type of tumor, patient's demographic information, etc. And whether MRI findings changed the initial treatment plan.</p></div><div><h3>Conclusions</h3><p>MRI played an essential role in the preoperative staging of breast cancer in our study, modifying therapeutic planning in approximately one-third of the cases and having a justified effect on most of them. We, therefore, support preoperative breast <span>MRI</span> in newly diagnosed breast cancer patients.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141581458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BALAD score predicts the recurrence and survival in the patients who underwent initial hepatectomy for HCC BALAD 评分可预测初次接受肝癌切除术患者的复发率和存活率
IF 2.3 4区 医学 Q3 ONCOLOGY Pub Date : 2024-07-02 DOI: 10.1016/j.suronc.2024.102097
Shigeki Nakagawa, Hiromitsu Hayashi, Rumi Itoyama, Yuki Kitano, Kosuke Mima, Hirohisa Okabe, Hideo Baba

Backgrounds

Several studies have indicated that BALAD score which includes the HCC tumor markers of HCC, AFP, AFP-L3%, DCP, and serum albumin and bilirubin value were good predictors of HCC patients for all treatment modalities. In this study, we aim to clarify the impact of BALAD score as the prognostic factor for HCC patients after curative surgery.

Methods

This study investigated 578 patients who underwent hepatectomy for HCC between January 2003 and May 2013. Cumulative recurrence rate, overall survival (OS), and clinicopathological parameters were analyzed according to the level of BALAD score.

Results

In patients with higher BALAD score, recurrence rate and OS was poor (p = 0.0015 and p < 0.0001, respectively). Multivariate analyses revealed independent risk factors for recurrence to be male (hazard ratio [HR] 1.52, P = 0.011), HCV-antibody positive (HR 1.33, P = 0.019), multiple tumors (HR 2.16, P < 0.0001), microvascular invasion (HR 1.45, P = 0.0035) and higher BALAD score (RR 1.70, P = 0.015). The independent risk factors for OS were multiple tumors (HR 1.52, P = 0.014), microvascular invasion (HR 1.53, P = 0.012), and higher BALAD score (RR 2.51, P = 0.0012).

Conclusion

BALAD score is associated with high recurrence rate and poor overall survival of the patients who underwent curative liver resection for HCC.

背景多项研究表明,包括HCC、AFP、AFP-L3%、DCP、血清白蛋白和胆红素值等HCC肿瘤标志物在内的BALAD评分是HCC患者接受所有治疗方式的良好预测指标。本研究旨在明确 BALAD 评分作为治愈性手术后预后因素对 HCC 患者的影响。方法 本研究调查了 2003 年 1 月至 2013 年 5 月间接受肝切除术治疗的 578 例 HCC 患者。结果 BALAD评分越高的患者,复发率和OS越低(分别为P = 0.0015和P < 0.0001)。多变量分析显示,男性(危险比 [HR] 1.52,P = 0.011)、HCV 抗体阳性(HR 1.33,P = 0.019)、多发肿瘤(HR 2.16,P < 0.0001)、微血管侵犯(HR 1.45,P = 0.0035)和 BALAD 评分较高(RR 1.70,P = 0.015)是复发的独立危险因素。多发肿瘤(HR 1.52,P = 0.014)、微血管侵犯(HR 1.53,P = 0.012)和较高的BALAD评分(RR 2.51,P = 0.0012)是影响OS的独立危险因素。
{"title":"BALAD score predicts the recurrence and survival in the patients who underwent initial hepatectomy for HCC","authors":"Shigeki Nakagawa,&nbsp;Hiromitsu Hayashi,&nbsp;Rumi Itoyama,&nbsp;Yuki Kitano,&nbsp;Kosuke Mima,&nbsp;Hirohisa Okabe,&nbsp;Hideo Baba","doi":"10.1016/j.suronc.2024.102097","DOIUrl":"10.1016/j.suronc.2024.102097","url":null,"abstract":"<div><h3>Backgrounds</h3><p>Several studies have indicated that BALAD score which includes the HCC tumor markers of HCC, AFP, AFP-L3%, DCP, and serum albumin and bilirubin value were good predictors of HCC patients for all treatment modalities. In this study, we aim to clarify the impact of BALAD score as the prognostic factor for HCC patients after curative surgery.</p></div><div><h3>Methods</h3><p>This study investigated 578 patients who underwent hepatectomy for HCC between January 2003 and May 2013. Cumulative recurrence rate, overall survival (OS), and clinicopathological parameters were analyzed according to the level of BALAD score.</p></div><div><h3>Results</h3><p>In patients with higher BALAD score, recurrence rate and OS was poor (p = 0.0015 and p &lt; 0.0001, respectively). Multivariate analyses revealed independent risk factors for recurrence to be male (hazard ratio [HR] 1.52, <em>P</em> = 0.011), HCV-antibody positive (HR 1.33, <em>P</em> = 0.019), multiple tumors (HR 2.16, <em>P</em> &lt; 0.0001), microvascular invasion (HR 1.45, <em>P</em> = 0.0035) and higher BALAD score (RR 1.70, <em>P</em> = 0.015). The independent risk factors for OS were multiple tumors (HR 1.52, <em>P</em> = 0.014), microvascular invasion (HR 1.53, <em>P</em> = 0.012), and higher BALAD score (RR 2.51, <em>P</em> = 0.0012).</p></div><div><h3>Conclusion</h3><p>BALAD score is associated with high recurrence rate and poor overall survival of the patients who underwent curative liver resection for HCC.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141636538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preventing futile surgery in Intrahepatic and Perihilar cholangiocarcinomas: Can we identify preoperative factors to improve patient selection and optimize outcomes? 防止肝内和肝周胆管癌的无效手术:我们能否确定术前因素以改进患者选择并优化疗效?
IF 2.3 4区 医学 Q3 ONCOLOGY Pub Date : 2024-06-29 DOI: 10.1016/j.suronc.2024.102096
Mahesh Goel , Gurudutt P. Varty , Shraddha Patkar , Meghana V. , Mufaddal Kazi , Kunal Nandy , Vikas Ostwal , Anant Ramaswamy , Kunal B. Gala , Nitin S. Shetty

Background

Intraoperative unresectability, postoperative deaths and early recurrences remain devastating futile events in the surgical management of Intrahepatic cholangiocarcinomas (iCCA) and Perihilar cholangiocarcinomas (pCCA). The present study aims to determine the preoperative predictors of futile surgery in cholangiocarcinomas.

Methods

Consecutive hepatectomies for iCCA and pCCA, between September 2010 and June 2022 were included. Futility of surgery was defined as either intraoperative unresectability, postoperative 30-day mortality or recurrence within six months of surgery. Multivariable logistic regression was used to identify predictors of futility.

Results

One hundred and fifty patients of iCCA and pCCA underwent surgery during the time period. Thirty-seven (38.1 %) out of 97 patients of iCCA and 25(47.16 %) out of 53 patients of pCCA underwent futile resection. The predictive factors of futile surgery for iCCA were tumour number (≥2) (OR, 9.705; 95%CI, 2.378–39.614; p = 0.002), serum aspartate transaminase (OR, 8.31; 95%CI, 2.796–24.703; p < 0.001) and serum CA-19.9 (>37 U/ml) (OR, 2.95; 95%CI, 1.051–8.283; p = 0.04). The predictive factors of futility for pCCA were lymph node involvement (OR, 7.636; 95%CI, 1.824–31.979; p = 0.005) and serum alkaline phosphatase (>562.5 U/L) (OR, 11.211; 95%CI, 1.752–71.750; p = 0.011).

Conclusion

Futile surgery was observed in over one third of our patients. Five strong preoperative predictors of futility were identified. Careful analysis of these factors may reduce futile surgical explorations.

背景:在肝内胆管癌(iCCA)和肝周胆管癌(pCCA)的手术治疗中,术中无法切除、术后死亡和早期复发仍然是毁灭性的徒劳事件。本研究旨在确定胆管癌术前无效手术的预测因素:方法:纳入2010年9月至2022年6月期间连续进行的iCCA和pCCA肝切除术。手术失败定义为术中无法切除、术后 30 天死亡或术后 6 个月内复发。多变量逻辑回归用于确定手术失败的预测因素:在此期间,150 名 iCCA 和 pCCA 患者接受了手术。97例iCCA患者中有37例(38.1%)接受了无效切除手术,53例pCCA患者中有25例(47.16%)接受了无效切除手术。肿瘤数目(≥2)(OR,9.705;95%CI,2.378-39.614;P = 0.002)、血清天门冬氨酸转氨酶(OR,8.31;95%CI,2.796-24.703;P 37 U/ml)(OR,2.95;95%CI,1.051-8.283;P = 0.04)是 iCCA 无效手术的预测因素。淋巴结受累(OR,7.636;95%CI,1.824-31.979;P = 0.005)和血清碱性磷酸酶(>562.5 U/L)(OR,11.211;95%CI,1.752-71.750;P = 0.011)是预测 pCCA 无效的因素:结论:超过三分之一的患者接受了无效手术。结论:我们的患者中有三分之一以上接受了无效手术。对这些因素进行仔细分析可减少无效手术的发生。
{"title":"Preventing futile surgery in Intrahepatic and Perihilar cholangiocarcinomas: Can we identify preoperative factors to improve patient selection and optimize outcomes?","authors":"Mahesh Goel ,&nbsp;Gurudutt P. Varty ,&nbsp;Shraddha Patkar ,&nbsp;Meghana V. ,&nbsp;Mufaddal Kazi ,&nbsp;Kunal Nandy ,&nbsp;Vikas Ostwal ,&nbsp;Anant Ramaswamy ,&nbsp;Kunal B. Gala ,&nbsp;Nitin S. Shetty","doi":"10.1016/j.suronc.2024.102096","DOIUrl":"10.1016/j.suronc.2024.102096","url":null,"abstract":"<div><h3>Background</h3><p>Intraoperative unresectability, postoperative deaths and early recurrences remain devastating futile events in the surgical management of Intrahepatic cholangiocarcinomas (iCCA) and Perihilar cholangiocarcinomas (pCCA). The present study aims to determine the preoperative predictors of futile surgery in cholangiocarcinomas.</p></div><div><h3>Methods</h3><p>Consecutive hepatectomies for iCCA and pCCA, between September 2010 and June 2022 were included. Futility of surgery was defined as either intraoperative unresectability, postoperative 30-day mortality or recurrence within six months of surgery. Multivariable logistic regression was used to identify predictors of futility.</p></div><div><h3>Results</h3><p>One hundred and fifty patients of iCCA and pCCA underwent surgery during the time period. Thirty-seven (38.1 %) out of 97 patients of iCCA and 25(47.16 %) out of 53 patients of pCCA underwent futile resection. The predictive factors of futile surgery for iCCA were tumour number (≥2) (OR, 9.705; 95%CI, 2.378–39.614; p = 0.002), serum aspartate transaminase (OR, 8.31; 95%CI, 2.796–24.703; p &lt; 0.001) and serum CA-19.9 (&gt;37 U/ml) (OR, 2.95; 95%CI, 1.051–8.283; p = 0.04). The predictive factors of futility for pCCA were lymph node involvement (OR, 7.636; 95%CI, 1.824–31.979; p = 0.005) and serum alkaline phosphatase (&gt;562.5 U/L) (OR, 11.211; 95%CI, 1.752–71.750; p = 0.011).</p></div><div><h3>Conclusion</h3><p>Futile surgery was observed in over one third of our patients. Five strong preoperative predictors of futility were identified. Careful analysis of these factors may reduce futile surgical explorations.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141535931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes of right sleeve lower lobectomy vs. lower bilobectomy for lung malignancies 右袖状下肺叶切除术与下双叶切除术治疗肺部恶性肿瘤的疗效对比
IF 2.3 4区 医学 Q3 ONCOLOGY Pub Date : 2024-06-29 DOI: 10.1016/j.suronc.2024.102100
Justin Issard , Geoffrey Brioude , Delphine Mitilian , Dominique Fabre , Vincent Thomas de Montpreville , Amir Hanna , Caroline Caramella , Cécile Lepechoux , Benjamin Besse , Olaf Mercier , Elie Fadel

Objectives

Lower bilobectomy (LBL) leaves a residual pleural space potentially associated with adverse postoperative outcomes. In selected patients, right sleeve lower lobectomy (RSLL) with anastomosis between the middle lobe bronchus and intermediate bronchus is feasible. The outcomes of RSLL and LBL have not been compared. The aim of this study was to compare post-operative and long-term outcomes of RSLL and LBL in patients with lung cancer.

Methods

We retrospectively included patients managed by RSLL or LBL at our referral chest-surgery institution between 2001 and 2019. Post-operative complications and mortality were compared. Kaplan-Meier curves were plotted to compare overall and disease-free survival rates.

Results

We identified 23 patients with RSLL and 96 with LBL. Postoperative mortality was 9 % after RSLL and 5 % after LBL (p = 0.41). Bronchial fistula developed in 3 (13 %) RSLL patients and 6 (6 %) LBL patients (p = 0.23). Pleural space complications were significantly less common after RSLL (4/23 [17 %] vs. 45/96 [47 %], p = 0.03). Long-term vital capacity was significantly higher in the RSLL group (91 % vs. 64 %, p < 0.01). Five-year survival did not differ significantly between groups (84 % vs. 72 %, p = 0.09).

Conclusions

RSLL was associated with similar postoperative mortality and long-term survival compared to LBL. However, pleural space complications were less common and lung function was better after RSLL than after LBL. When feasible, RSLL may deserve preference over LBL in patients with lung cancer managed at highly experienced centres.

目的 双下叶切除术(LBL)留下的残余胸膜腔可能与术后不良预后有关。在经过选择的患者中,可行右袖状下叶切除术(RSLL),并在中叶支气管和中间支气管之间进行吻合。RSLL 和 LBL 的疗效尚未进行过比较。本研究旨在比较 RSLL 和 LBL 对肺癌患者的术后和长期疗效。比较了术后并发症和死亡率。绘制了 Kaplan-Meier 曲线,以比较总生存率和无病生存率。RSLL 术后死亡率为 9%,LBL 术后死亡率为 5%(P = 0.41)。3例(13%)RSLL 患者和 6 例(6%)LBL 患者出现支气管瘘(p = 0.23)。RSLL 后胸膜腔并发症的发生率明显较低(4/23 [17 %] vs. 45/96 [47 %],p = 0.03)。RSLL 组的长期生存能力明显更高(91% 对 64%,P = 0.01)。结论与 LBL 相比,RSLL 的术后死亡率和长期存活率相似。但 RSLL 术后胸膜腔并发症较少,肺功能也优于 LBL 术。在可行的情况下,对于在经验丰富的中心接受治疗的肺癌患者来说,RSLL 比 LBL 更受青睐。
{"title":"Outcomes of right sleeve lower lobectomy vs. lower bilobectomy for lung malignancies","authors":"Justin Issard ,&nbsp;Geoffrey Brioude ,&nbsp;Delphine Mitilian ,&nbsp;Dominique Fabre ,&nbsp;Vincent Thomas de Montpreville ,&nbsp;Amir Hanna ,&nbsp;Caroline Caramella ,&nbsp;Cécile Lepechoux ,&nbsp;Benjamin Besse ,&nbsp;Olaf Mercier ,&nbsp;Elie Fadel","doi":"10.1016/j.suronc.2024.102100","DOIUrl":"10.1016/j.suronc.2024.102100","url":null,"abstract":"<div><h3>Objectives</h3><p>Lower bilobectomy (LBL) leaves a residual pleural space potentially associated with adverse postoperative outcomes. In selected patients, right sleeve lower lobectomy (RSLL) with anastomosis between the middle lobe bronchus and intermediate bronchus is feasible. The outcomes of RSLL and LBL have not been compared. The aim of this study was to compare post-operative and long-term outcomes of RSLL and LBL in patients with lung cancer.</p></div><div><h3>Methods</h3><p>We retrospectively included patients managed by RSLL or LBL at our referral chest-surgery institution between 2001 and 2019. Post-operative complications and mortality were compared. Kaplan-Meier curves were plotted to compare overall and disease-free survival rates.</p></div><div><h3>Results</h3><p>We identified 23 patients with RSLL and 96 with LBL. Postoperative mortality was 9 % after RSLL and 5 % after LBL (<em>p</em> = 0.41). Bronchial fistula developed in 3 (13 %) RSLL patients and 6 (6 %) LBL patients (<em>p</em> = 0.23). Pleural space complications were significantly less common after RSLL (4/23 [17 %] vs. 45/96 [47 %], <em>p</em> = 0.03). Long-term vital capacity was significantly higher in the RSLL group (91 % vs. 64 %, <em>p</em> &lt; 0.01). Five-year survival did not differ significantly between groups (84 % vs. 72 %, <em>p</em> = 0.09).</p></div><div><h3>Conclusions</h3><p>RSLL was associated with similar postoperative mortality and long-term survival compared to LBL. However, pleural space complications were less common and lung function was better after RSLL than after LBL. When feasible, RSLL may deserve preference over LBL in patients with lung cancer managed at highly experienced centres.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141638479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative evaluation of continence and potency after radical prostatectomy: Robotic vs. laparoscopic approaches, validating LAP-01 trial 根治性前列腺切除术后尿失禁和排尿能力的比较评估:机器人与腹腔镜方法的比较,验证 LAP-01 试验。
IF 2.3 4区 医学 Q3 ONCOLOGY Pub Date : 2024-06-28 DOI: 10.1016/j.suronc.2024.102098
Alicia López-Abad , Gerardo Server Gómez , Juan Pablo Loyola Maturana , Inés Giménez Andreu , Argimiro Collado Serra , Augusto Wong Gutiérrez , Juan Boronat Catalá , Pedro de Pablos Rodríguez , Álvaro Gómez-Ferrer , Juan Casanova Ramón-Borja , Miguel Ramírez Backhaus

Background

Minimally invasive techniques have demonstrated several advantages over the open approach. In the field of prostate cancer, the LAP-01 trial demonstrated the superiority of robotic-assisted radical prostatectomy (RARP) over laparoscopic radical prostatectomy (LRP) when comparing continence at 3-month after surgery, with no statistically significant differences at 6 and 12 months of follow-up.

Objectives

Externally validate the LAP-01 study and compare functional outcomes between the two minimally invasive approaches.

Material and methods

This retrospective study, conducted by a single surgeon (MRB), utilized data from a prospectively collected database, which included patients who underwent both RARP or LRP. Data regarding baseline characteristics, continence (assessed through the 24-h Pad test and ICIQ questionnaire) and potency were collected at multiple time points: 1 and 6 weeks after catheter removal, 3-, 6-, and 12-months post-surgery.

Results

The study encompasses 601 patients, 455 who underwent LRP and 146 RARP. The median age at diagnosis was 64 for LRP and 62 for RARP, while the median PSA levels at diagnosis were 6.7 ng/mL for LRP and 6.5 ng/mL for RARP. Bilateral nerve-sparing procedures were performed in 34.07 % of LRP cases and 51.37 % of RARP cases.

RARP exhibited a significant advantage over LRP both in continence and potency. Continence rates at 3-, 6- and 9-month after radical prostatectomy (RP) were 36.43 %, 61.86 % and 79.87 % for LRP, compared to 50.98 %, 69.87 % and 91.69 % for RARP. Potency rates at the same intervals were 0.90 %, 3.16 % and 6.39 % for LRP, and 6.19 %, 9.16 % and 18.96 % for RARP. These rates were more pronounced in patients with bilateral nerve-sparing.

Conclusion

Our study demonstrates that RARP results in significantly better continence recovery and superior potency outcomes throughout the entire follow-up period compared to LRP, even at the beginning of the robotic approach learning curve.

背景:与开放式方法相比,微创技术具有多项优势。在前列腺癌领域,LAP-01 试验表明,与腹腔镜前列腺癌根治术(LRP)相比,机器人辅助前列腺癌根治术(RARP)在术后 3 个月的尿失禁情况方面更具优势,而在随访 6 个月和 12 个月时,两者的差异无统计学意义:外部验证 LAP-01 研究,比较两种微创方法的功能结果:这项回顾性研究由一名外科医生(MRB)进行,利用了前瞻性数据库中的数据,其中包括同时接受 RARP 或 LRP 的患者。在多个时间点收集了有关基线特征、尿失禁(通过 24 小时垫测试和 ICIQ 问卷进行评估)和排尿能力的数据:结果:这项研究包括 601 名患者,其中 455 人接受了 LRP,146 人接受了 RARP。LRP患者诊断时的中位年龄为64岁,RARP患者为62岁;LRP患者诊断时的中位PSA水平为6.7纳克/毫升,RARP患者为6.5纳克/毫升。34.07%的LRP病例和51.37%的RARP病例进行了双侧神经保留手术。与 LRP 相比,RARP 在通畅性和有效性方面都有明显优势。根治性前列腺切除术(RP)后3个月、6个月和9个月的尿失禁率,LRP分别为36.43%、61.86%和79.87%,而RARP分别为50.98%、69.87%和91.69%。在相同时间间隔内,LRP 的效力率分别为 0.90 %、3.16 % 和 6.39 %,RARP 的效力率分别为 6.19 %、9.16 % 和 18.96 %。这些比率在双侧神经保留的患者中更为明显:我们的研究表明,与 LRP 相比,RARP 在整个随访期间的尿失禁恢复情况明显更好,药效也更佳,即使在机器人方法学习曲线的初期也是如此。
{"title":"Comparative evaluation of continence and potency after radical prostatectomy: Robotic vs. laparoscopic approaches, validating LAP-01 trial","authors":"Alicia López-Abad ,&nbsp;Gerardo Server Gómez ,&nbsp;Juan Pablo Loyola Maturana ,&nbsp;Inés Giménez Andreu ,&nbsp;Argimiro Collado Serra ,&nbsp;Augusto Wong Gutiérrez ,&nbsp;Juan Boronat Catalá ,&nbsp;Pedro de Pablos Rodríguez ,&nbsp;Álvaro Gómez-Ferrer ,&nbsp;Juan Casanova Ramón-Borja ,&nbsp;Miguel Ramírez Backhaus","doi":"10.1016/j.suronc.2024.102098","DOIUrl":"10.1016/j.suronc.2024.102098","url":null,"abstract":"<div><h3>Background</h3><p>Minimally invasive techniques have demonstrated several advantages over the open approach. In the field of prostate cancer, the LAP-01 trial demonstrated the superiority of robotic-assisted radical prostatectomy (RARP) over laparoscopic radical prostatectomy (LRP) when comparing continence at 3-month after surgery, with no statistically significant differences at 6 and 12 months of follow-up.</p></div><div><h3>Objectives</h3><p>Externally validate the LAP-01 study and compare functional outcomes between the two minimally invasive approaches.</p></div><div><h3>Material and methods</h3><p>This retrospective study, conducted by a single surgeon (MRB), utilized data from a prospectively collected database, which included patients who underwent both RARP or LRP. Data regarding baseline characteristics, continence (assessed through the 24-h Pad test and ICIQ questionnaire) and potency were collected at multiple time points: 1 and 6 weeks after catheter removal, 3-, 6-, and 12-months post-surgery.</p></div><div><h3>Results</h3><p>The study encompasses 601 patients, 455 who underwent LRP and 146 RARP. The median age at diagnosis was 64 for LRP and 62 for RARP, while the median PSA levels at diagnosis were 6.7 ng/mL for LRP and 6.5 ng/mL for RARP. Bilateral nerve-sparing procedures were performed in 34.07 % of LRP cases and 51.37 % of RARP cases.</p><p>RARP exhibited a significant advantage over LRP both in continence and potency. Continence rates at 3-, 6- and 9-month after radical prostatectomy (RP) were 36.43 %, 61.86 % and 79.87 % for LRP, compared to 50.98 %, 69.87 % and 91.69 % for RARP. Potency rates at the same intervals were 0.90 %, 3.16 % and 6.39 % for LRP, and 6.19 %, 9.16 % and 18.96 % for RARP. These rates were more pronounced in patients with bilateral nerve-sparing.</p></div><div><h3>Conclusion</h3><p>Our study demonstrates that RARP results in significantly better continence recovery and superior potency outcomes throughout the entire follow-up period compared to LRP, even at the beginning of the robotic approach learning curve.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transvaginal natural orifice transluminal endoscopic surgery (VNOTES) retroperitoneal sentinel lymph node BIOPSY compared with conventional laparoscopy in patients with endometrial cancer 子宫内膜癌患者经阴道自然孔腔内镜手术(VNOTES)腹膜后前哨淋巴结BIOPSY与传统腹腔镜手术的比较。
IF 2.3 4区 医学 Q3 ONCOLOGY Pub Date : 2024-06-28 DOI: 10.1016/j.suronc.2024.102099
Cihan Comba , Sema Karakas , Sakir Volkan Erdogan , Omer Demir , Erkan Şimşek , Fatma Karasabanoglu , Gokhan Demirayak , Isa Aykut Ozdemir

Introduction

To explore the possibility of treatment with VNOTES sentinel lymph node dissection concept in patients with endometrial cancer.

Methods

Patients who underwent VNOTES sentinel lymph node biopsy with the Comba modification were compared to patients who underwent conventional laparoscopic sentinel lymph node biopsy performed by the same surgical team. A total of 38 patients who underwent sentinel lymph node biopsy + total laparoscopic hysterectomy and bilateral salpingo-oophorectomy (BSO) were compared with 19 patients who underwent VNOTES retroperitoneal sentinel lymph node biopsy + hysterectomy and BSO. Surgical steps were described.

Results

The average operation time, perioperative blood loss, the number of sentinel lymph nodes, presence of complications, and preoperative-postoperative hemoglobin-hematocrit differences, tumor stages, grades, largest tumor diameter, depths of invasion, and histological subtypes were similar in both the VNOTES and conventional laparoscopy groups. The postoperative pain scores were lower and the hospital stay was shorter in the VNOTES group than in the conventional laparoscopy group. No disease recurrence had been detected in either group at the time of writing.

Conclusion

Compared to conventional laparoscopy, sentinel lymph node biopsy with the VNOTES technique provides similar surgical results and is more advantageous in terms of postoperative pain and hospital length of stay.

简介:目的探讨在子宫内膜癌患者中使用VNOTES前哨淋巴结清扫概念进行治疗的可能性:将接受康巴改良VNOTES前哨淋巴结活检术的患者与接受由同一手术团队实施的传统腹腔镜前哨淋巴结活检术的患者进行比较。38名接受前哨淋巴结活检+全腹腔镜子宫切除术和双侧输卵管切除术(BSO)的患者与19名接受VNOTES腹膜后前哨淋巴结活检+子宫切除术和BSO的患者进行了比较。对手术步骤进行了描述:结果:VNOTES组和传统腹腔镜组的平均手术时间、围手术期失血量、前哨淋巴结数量、并发症发生率、术前术后血红蛋白-血细胞比容差异、肿瘤分期、分级、最大肿瘤直径、浸润深度和组织学亚型相似。与传统腹腔镜手术组相比,VNOTES组的术后疼痛评分更低,住院时间更短。在撰写本报告时,两组患者均未发现疾病复发:结论:与传统腹腔镜手术相比,采用VNOTES技术进行前哨淋巴结活检的手术效果相似,但在术后疼痛和住院时间方面更具优势。
{"title":"Transvaginal natural orifice transluminal endoscopic surgery (VNOTES) retroperitoneal sentinel lymph node BIOPSY compared with conventional laparoscopy in patients with endometrial cancer","authors":"Cihan Comba ,&nbsp;Sema Karakas ,&nbsp;Sakir Volkan Erdogan ,&nbsp;Omer Demir ,&nbsp;Erkan Şimşek ,&nbsp;Fatma Karasabanoglu ,&nbsp;Gokhan Demirayak ,&nbsp;Isa Aykut Ozdemir","doi":"10.1016/j.suronc.2024.102099","DOIUrl":"10.1016/j.suronc.2024.102099","url":null,"abstract":"<div><h3>Introduction</h3><p>To explore the possibility of treatment with VNOTES sentinel lymph node dissection concept in patients with endometrial cancer.</p></div><div><h3>Methods</h3><p>Patients who underwent VNOTES sentinel lymph node biopsy with the Comba modification were compared to patients who underwent conventional laparoscopic sentinel lymph node biopsy performed by the same surgical team. A total of 38 patients who underwent sentinel lymph node biopsy + total laparoscopic hysterectomy and bilateral salpingo-oophorectomy (BSO) were compared with 19 patients who underwent VNOTES retroperitoneal sentinel lymph node biopsy + hysterectomy and BSO. Surgical steps were described.</p></div><div><h3>Results</h3><p>The average operation time, perioperative blood loss, the number of sentinel lymph nodes, presence of complications, and preoperative-postoperative hemoglobin-hematocrit differences, tumor stages, grades, largest tumor diameter, depths of invasion, and histological subtypes were similar in both the VNOTES and conventional laparoscopy groups. The postoperative pain scores were lower and the hospital stay was shorter in the VNOTES group than in the conventional laparoscopy group. No disease recurrence had been detected in either group at the time of writing.</p></div><div><h3>Conclusion</h3><p>Compared to conventional laparoscopy, sentinel lymph node biopsy with the VNOTES technique provides similar surgical results and is more advantageous in terms of postoperative pain and hospital length of stay.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is surgical quality more important than radicality? Long-term outcomes of stage I–III colon cancer (SAKK 40/00) 手术质量比根治性更重要吗?I-III期结肠癌的长期疗效(SAKK 40/00)
IF 2.3 4区 医学 Q1 Medicine Pub Date : 2024-05-29 DOI: 10.1016/j.suronc.2024.102092
Christoph A. Maurer , Daniel Dietrich , Martin K. Schilling , Peter Brauchli , Katharina Kessler , Samuel A. Käser

Background

To prospectively determine the influence of variations of surgical radicality and surgical quality on long-term outcome in patients with stage I-III colon cancer.

Methods

From a prospective multicenter cohort study including 1040 patients undergoing surgery for colorectal cancer from 09/2001 to 06/2005 in nine Swiss and one German hospital, 423 patients with stage I-III colon cancer were selected and analyzed. Surgeons and pathologists filled in standardized forms prospectively assessing items of oncosurgical radicality and quality. Patients had standardized follow-up according to national guidelines.

Results

Follow-up was median 6.2 years (range 0.3–10.4) showing a 5-year disease-free survival/overall survival of 83 %/87 % in stage I (n = 85), 69 %/77 % in stage II (n = 187), and 53 %/61 % in stage III (n = 151) colon cancer. Despite remarkable variations of oncosurgical radicality and quality, the multivariate model revealed that mainly quality items correlated significantly with disease-free survival (surgical tumor lesion HR 2.12, p = 0.036, perioperative blood transfusion HR 1.67, p = 0.018, emergency resection HR 1.74, p = 0.035) and overall survival (early venous ligation HR 0.66, p = 0.023, surgical tumor lesion HR 2.28, p = 0.027, perioperative blood transfusion HR1.79, p = 0.010, emergency resection HR 1.88, p = 0.026), while radicality parameters (length of specimen, distance of the tumor to nearest bowel resection site, number of lymph nodes, height of resected mesocolon and of central vascular dissection) did not.

Conclusion

Surgical quality seems to have a stronger impact on oncologic long-term outcome in stage I – III colon cancer than surgical radicality.

背景为了前瞻性地确定手术根治性和手术质量的变化对 I-III 期结肠癌患者长期预后的影响。方法从一项前瞻性多中心队列研究中筛选并分析了 423 名 I-III 期结肠癌患者,该研究包括 9 家瑞士医院和 1 家德国医院在 2001 年 9 月至 2005 年 6 月期间接受手术治疗的 1040 名结肠癌患者。外科医生和病理学家填写了标准化表格,对手术根治性和质量进行了前瞻性评估。结果随访时间中位数为 6.2 年(0.3-10.4 年不等),显示结肠癌 I 期(85 人)的 5 年无病生存率/总生存率为 83%/87%,II 期(187 人)为 69%/77%,III 期(151 人)为 53%/61%。尽管手术根治性和质量存在明显差异,但多变量模型显示,主要质量项目与无病生存率(手术肿瘤病变 HR 2.12,p = 0.036,围手术期输血 HR 1.67,p = 0.018,急诊切除 HR 1.74,p = 0.035)和总生存率(早期静脉结扎 HR 0.66,p = 0.023,手术肿瘤病变 HR 2.28,p = 0.027,围手术期输血 HR1.79,p = 0.010,急诊切除 HR1.88,p = 0.026),而根治性参数(标本长度、肿瘤到最近肠切除部位的距离、淋巴结数量、切除结肠系膜高度和中央血管清扫)则没有影响。
{"title":"Is surgical quality more important than radicality? Long-term outcomes of stage I–III colon cancer (SAKK 40/00)","authors":"Christoph A. Maurer ,&nbsp;Daniel Dietrich ,&nbsp;Martin K. Schilling ,&nbsp;Peter Brauchli ,&nbsp;Katharina Kessler ,&nbsp;Samuel A. Käser","doi":"10.1016/j.suronc.2024.102092","DOIUrl":"https://doi.org/10.1016/j.suronc.2024.102092","url":null,"abstract":"<div><h3>Background</h3><p>To prospectively determine the influence of variations of surgical radicality and surgical quality on long-term outcome in patients with stage I-III colon cancer.</p></div><div><h3>Methods</h3><p>From a prospective multicenter cohort study including 1040 patients undergoing surgery for colorectal cancer from 09/2001 to 06/2005 in nine Swiss and one German hospital, 423 patients with stage I-III colon cancer were selected and analyzed. Surgeons and pathologists filled in standardized forms prospectively assessing items of oncosurgical radicality and quality. Patients had standardized follow-up according to national guidelines.</p></div><div><h3>Results</h3><p>Follow-up was median 6.2 years (range 0.3–10.4) showing a 5-year disease-free survival/overall survival of 83 %/87 % in stage I (n = 85), 69 %/77 % in stage II (n = 187), and 53 %/61 % in stage III (n = 151) colon cancer. Despite remarkable variations of oncosurgical radicality and quality, the multivariate model revealed that mainly quality items correlated significantly with disease-free survival (surgical tumor lesion HR 2.12, p = 0.036, perioperative blood transfusion HR 1.67, p = 0.018, emergency resection HR 1.74, p = 0.035) and overall survival (early venous ligation HR 0.66, p = 0.023, surgical tumor lesion HR 2.28, p = 0.027, perioperative blood transfusion HR1.79, p = 0.010, emergency resection HR 1.88, p = 0.026), while radicality parameters (length of specimen, distance of the tumor to nearest bowel resection site, number of lymph nodes, height of resected mesocolon and of central vascular dissection) did not.</p></div><div><h3>Conclusion</h3><p>Surgical quality seems to have a stronger impact on oncologic long-term outcome in stage I – III colon cancer than surgical radicality.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141249956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MRI navigation surgery, including lateral pelvic lymph node dissection following chemoradiotherapy, improves local control and functional preservation of the middle to low rectal cancer 磁共振成像导航手术(包括化疗后的盆腔侧淋巴结清扫术)可提高中低位直肠癌的局部控制率和功能保留率
IF 2.3 4区 医学 Q1 Medicine Pub Date : 2024-05-28 DOI: 10.1016/j.suronc.2024.102093
Madoka Hamada , Hiroaki Kurokawa , Toshinori Kobayashi , Yoshiko Uemura

Purpose

The purpose of this study is to examine the appropriateness of MRI navigation surgery following chemoradiotherapy (CRT), including lateral pelvic lymph node dissection (LLND) for middle to low rectal cancer.

Methods

Forty-three consecutive patients with cT2-4b rectal cancer within 10 cm from the anal verge who underwent laparoscopic radical surgery following CRT (45–50.4Gy + S1 80mg/m2) from January 2014 and February 2020 were analyzed. We decided on the operative procedure, including LLND, based on the restaging MRI. We examined the rates of 3-year postoperative local pelvic recurrence, permanent stoma, and recurrent risk factors (Group S). We also compared the results to that of the fourteen patients who enrolled in the previous phase II trial and underwent laparoscopic radical surgery following CRT (40Gy + S-1 (80mg/m2) or UFT (300 mg/m2)) for consecutive cT2-4b rectal cancer below the peritoneal reflection. The operative procedure was decided at the initial MRI diagnosis, and the LLND was not performed (Group P).

Results

We had no local pelvic recurrence in Group S, and the three-year local pelvic recurrence-free survival was significantly better in Group S than P (100 % in S 85.1 % in P, p < 0.05). The permanent stoma rate was not different between the Groups, irrespective of the significantly high rate of cCRM(+) in Group S. The Cox proportional hazards model for significant factors of recurrence on the univariate analysis revealed that ycM and ycEMVI scores were independently significant (p < 0.001).

Conclusion

MRI navigation surgery, including LLND for rectal cancer following chemoradiotherapy, improves local control and functional preservation.

方法对2014年1月至2020年2月期间连续接受腹腔镜根治术的43例距肛缘10厘米以内的cT2-4b直肠癌患者进行分析,这些患者在接受CRT(45-50.4Gy + S1 80mg/m2)治疗后接受了腹腔镜根治术。我们根据 MRI 重分期结果决定手术方式,包括 LLND。我们检查了术后 3 年盆腔局部复发率、永久造口率和复发风险因素(S 组)。我们还将结果与之前参加II期试验的14名腹腔镜根治术患者的结果进行了比较,这些患者因腹膜反光以下连续性cT2-4b直肠癌接受了CRT(40Gy + S-1 (80mg/m2) 或 UFT (300 mg/m2))治疗。结果S组无局部盆腔复发,S组的三年无局部盆腔复发生存率明显优于P组(S组为100%,P组为85.1%,P< 0.05)。结论MRI导航手术,包括化放疗后直肠癌LLND,可改善局部控制和功能保留。
{"title":"MRI navigation surgery, including lateral pelvic lymph node dissection following chemoradiotherapy, improves local control and functional preservation of the middle to low rectal cancer","authors":"Madoka Hamada ,&nbsp;Hiroaki Kurokawa ,&nbsp;Toshinori Kobayashi ,&nbsp;Yoshiko Uemura","doi":"10.1016/j.suronc.2024.102093","DOIUrl":"https://doi.org/10.1016/j.suronc.2024.102093","url":null,"abstract":"<div><h3>Purpose</h3><p>The purpose of this study is to examine the appropriateness of MRI navigation surgery following chemoradiotherapy (CRT), including lateral pelvic lymph node dissection (LLND) for middle to low rectal cancer.</p></div><div><h3>Methods</h3><p>Forty-three consecutive patients with cT2-4b rectal cancer within 10 cm from the anal verge who underwent laparoscopic radical surgery following CRT (45–50.4Gy + S1 80mg/m2) from January 2014 and February 2020 were analyzed. We decided on the operative procedure, including LLND, based on the restaging MRI. We examined the rates of 3-year postoperative local pelvic recurrence, permanent stoma, and recurrent risk factors (Group S). We also compared the results to that of the fourteen patients who enrolled in the previous phase II trial and underwent laparoscopic radical surgery following CRT (40Gy + S-1 (80mg/m2) or UFT (300 mg/m2)) for consecutive cT2-4b rectal cancer below the peritoneal reflection. The operative procedure was decided at the initial MRI diagnosis, and the LLND was not performed (Group P).</p></div><div><h3>Results</h3><p>We had no local pelvic recurrence in Group S, and the three-year local pelvic recurrence-free survival was significantly better in Group S than P (100 % in S 85.1 % in P, p &lt; 0.05). The permanent stoma rate was not different between the Groups, irrespective of the significantly high rate of cCRM(+) in Group S. The Cox proportional hazards model for significant factors of recurrence on the univariate analysis revealed that ycM and ycEMVI scores were independently significant (p &lt; 0.001).</p></div><div><h3>Conclusion</h3><p>MRI navigation surgery, including LLND for rectal cancer following chemoradiotherapy, improves local control and functional preservation.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141332965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Surgical Oncology-Oxford
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1